Komori
Kaken Pharmaceutical (4521) · FactFirst stated

Change in Reporting Segments Following the Absorption of Kaken Real Estate Services

First written in FY2017-Q3. . Latest entry: FY2017-Q3.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Transfer of real estate assets to the pharmaceutical segment following the absorption-type merger of 科研不動産サービス株式会社A theme 1 companies write about · 0 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2017-Q3First statedAnnual report

    「Following the absorption on 31 March 2016 of Kaken Real Estate Services Co., Ltd., our wholly owned consolidated subsidiary, certain assets in the “Real Estate Business” segment held by that subsidiary have been reclassified to the “Pharmaceuticals” reporting segment from the fourth quarter of the previous consolidated fiscal year.」

    Following the absorption of Kaken Real Estate Services Co., Ltd., certain assets were reclassified from the Real Estate Business segment to the Pharmaceuticals segment from the fourth quarter after 31 March 2016. Comparative information was also prepared using the revised segment classification.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Kaken Pharmaceutical's next results are scheduled for 2026-11-09. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.